Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)
2026 · 3rd Quarter (July 1 - Sep 30)
ULTRAGENYX PHARMACEUTICAL INC.
Filed by ALPINE GROUP PARTNERS, LLC..
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 18, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- ALPINE GROUP PARTNERS, LLC.
- Filing UUID
- 1c0764eb-6da5-4ac9-a80c-ff2d5e1085e0
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)
Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases like Sanfilippo syndrome Type A, Duchenne Muscular Dystrophy (DMD), and Metachromatic Leukodystrophy (MLD)
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.